Rubius Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Rubius Therapeutics (Nasdaq: RUBY) announced that CEO Pablo J. Cagnoni and the executive team will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 11:20 a.m. EST. A live audio webcast will be available on the company’s website, with a replay accessible for 90 days post-event.

Rubius Therapeutics is focused on developing Red Cell Therapeutics™, a proprietary platform aimed at treating cancer and autoimmune diseases. The company has been recognized as a top workplace in Massachusetts and Rhode Island.

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, and the executive management team will participate in a fireside chat at the 10^th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 11:20 a.m. EST.

A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.

About Rubius Therapeutics

Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was recently named among the Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.

Contacts:

Investors
Elhan Webb, CFA, VP Investor Relations
elhan.webb@rubiustx.com

Media
Marissa Hanify, Director, Corporate Communications
marissa.hanify@rubiustx.com

Dan Budwick, 1AB
+1 (973) 271-6085
dan@1abmedia.com

FAQ

When will Rubius Therapeutics participate in the SVB Leerink Global Healthcare Conference?

Rubius Therapeutics will participate in the conference on February 25, 2021, at 11:20 a.m. EST.

Where can I watch the Rubius Therapeutics fireside chat?

You can watch the fireside chat live on the Investors & Media section of the Rubius Therapeutics website.

What is Rubius Therapeutics known for?

Rubius Therapeutics is known for developing Red Cell Therapeutics™, aiming to create new medicines for cancer and autoimmune diseases.

Is there a replay available for the Rubius Therapeutics conference presentation?

Yes, an archived replay of the presentation will be available for 90 days after the event.

What recognition has Rubius Therapeutics received recently?

Rubius Therapeutics was named among the Top Places to Work in Massachusetts and recognized as a top workplace in Rhode Island.